GDP, 400mM Ammonium Salt Solution
GDP, 400mM Ammonium Salt Solution - N (Normal) is backordered and will ship as soon as it is back in stock.
Couldn't load pickup availability
Shipping notes
Shipping notes
Related Products
Specifications
Specifications
-
Catalog No.R2-046
-
CAS No.146-91-8(free acid)
-
SMILESO=C1C(N=CN2[C@H]3[C@H](O)[C@H](O)[C@@H](COP(OP([O-])([O-])=O)([O-])=O)O3)=C2N=C(N)N1
-
Molecular FormulaC10H15N5O11P2 (free acid)
-
Molecular Weight443.20 (free acid)
-
AppearanceClear colorless solution
-
PurityHPLC≥98.0%
-
Storage Condition-20℃
Documentation
Documentation
-
Catalog No.R2-046
-
CAS No.146-91-8(free acid)
-
SMILESO=C1C(N=CN2[C@H]3[C@H](O)[C@H](O)[C@@H](COP(OP([O-])([O-])=O)([O-])=O)O3)=C2N=C(N)N1
-
Molecular FormulaC10H15N5O11P2 (free acid)
-
Molecular Weight443.20 (free acid)
-
AppearanceClear colorless solution
-
PurityHPLC≥98.0%
-
Storage Condition-20℃
Why choose Hongene?
Trusted Partner in Nucleic Acid
Integrated Supply & Commercial Scale
With 26+ years of expertise, we control a secure supply chain for RNA raw materials and provide reliable GMP-grade oligo synthesis from research to commercial kilogram-scale production.
Proprietary Technology & IP
Our proprietary Chemoenzymatic Ligation Platform combines chemical andenzymatic methods, enabling high-putity, cost-effective, and large-scale production of RNA-based therapeutics.
Rigorous Quality
We implement multiple stringent QC steps, maintain ISO certifications, and ensure >99% batch-to-batch consistency, reducing scale-up and PPQ risks.
Manufacturing Scalability
Hongene operates 1.67 million sq. ft Oligonucleotide Manufacturing Facility, with advanced equipments including multiple OligoPilot™ and OligoProcess™ synthesizers (10-1800 mmol). 48 flexible production lines enable one-stop seamless scaling-up of API production from gram-level to tons and acheive high purity of 98%, meeting NMPA, FDA, and EMA standards.
Global Business Network
Our products and services reach over 40 countries and regions, supporting around 3,000 clients worldwide.
